脾切除术对大鼠海马tau表达的影响

目的 评价脾切除术对大鼠海马tau表达的影响.方法 SD大鼠105只,随机分为3组,正常对照组(A组,n=15)不给予任何处理,麻醉组(B组,n=45)仅吸入1.5%异氟醚2 h,手术+麻醉组(C组,n=45)吸入1.5%异氟醚(吸入2 h)麻醉下实施脾切除术.B组和C组分别于麻醉后或术后1、3、7 d时处死15只大鼠,取海马组织,测定海马IL-1β mRNA、TNF-α mRNA、IL-1β、TNF-α、总tau、苏氨酸第205位点磷酸化tau(pT205 tau)、丝氨酸第396位点磷酸化tau(pS396 tau)、总糖原合成酶-3β(GSK-3β)和磷酸化GSK-3β(p-GSK-3β)的表达水平.结果 与A组比较,B组各时点IL-1β mRNA、TNF-α mRNA、IL-1β、TNF-α、总tau、pT205 tau、pS396 tau、GSK-3β和p-GSK-3β的表达水平差异无统计学意义(P＞0.05),C组术后IL-1βmRNA、TNF-α mRNA、IL-1β、pT205 tau和pS396 tau的表达上调,p-GSK-3β表达下调(P＜0.05或0.01).结论 手术创伤可导致大鼠海马tau磷酸化,其机制与手术创伤诱发炎性反应,从而激活GSK-3β有关.     

No association of psychosis in Alzheimer disease with neurodegenerative pathway genes

Psychotic symptoms occur in approximately 40% of subjects with Alzheimer disease (AD with psychosis; AD + P) and identify a subgroup with more rapid cognitive decline. We evaluated in 867 AD subjects the association of AD + P with genes which may modify the pathological process via effects on the accumulation of amyloid beta (Aβ) protein and/or hyperphosphorylated microtubule-associated protein tau (MAPT): amyloid precursor protein (APP), beta-site amyloid precursor protein cleaving enzyme (BACE1), sortilin-related receptor (SORL1), and MAPT. Each gene was thoroughly interrogated with tag single-nucleotide polymorphisms (SNPs), and gene-based tests were used to enhance power. We found no association of these genes with AD + P.     

Repression of tau hyperphosphorylation by chronic endurance exercise in aged transgenic mouse model of tauopathies

The present study was undertaken to investigate whether chronic endurance exercise affects tau phosphorylation levels in the brain with Alzheimer's disease (AD)‐like pathology. To address this, the transgenic (Tg) mouse model of tauopathies, Tg‐NSE/htau23, which expresses human tau23 in the brain, was chosen. Animals were subjected to chronic exercise for 3 months from 16 months of age. The exercised Tg mouse groups were treadmill run at speeds of 12 m/min (intermediate exercise group) or 19 m/min (high exercise group) for 1 hr/day, 5 days/week, during the 3‐month period. Chronic endurance exercise in Tg mice increased the expression of Cu/Zn‐superoxide dismutase (SOD) and catalase, and also their enzymatic activities in the brain. In parallel, chronic exercise in Tg mice up‐regulated the expression of phospho‐PKCα, phospho‐AKT, and phospho‐PI3K, and down‐regulated the expressions of phospho‐PKA, phosphor‐p38, phospho‐JNK, and phospho‐ERK. Moreover, chronic exercise up‐regulated both cytosolic and nuclear levels of β‐catenin, and the expression of T‐cell factor‐4 (Tcf‐4) and cyclin D1 in the brain. As a consequence of such changes, the levels of phospho‐tau in the brain of Tg mice were markedly decreased after exercise. Immunohistochemical analysis showed an exercised‐induced decrease of the phospho‐tau levels in the CA3 subregion of the hippocampus. These results suggest that chronic endurance exercise may provide a therapeutic potential to alleviate the tau pathology. © 2009 Wiley‐Liss, Inc.     

Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology

The inheritance of the ε4 allele of the apolipoprotein E ( apoE ) gene is the major genetic risk factor for developing late-onset Alzheimer disease. In transgenic mice overexpressing amyloid precursor protein (APP), replacing the endogenous mouse apoE gene with the human apolipoprotein E4 ( apoE4 ) gene alters the distribution of amyloid-β (Aβ) deposits from the brain parenchyma to the vasculature. However, the effects of this distribution on the onset and progression of tau pathology remain to be established. To address this issue, we used a genetic approach to replace the endogenous apoE gene with the human apoE4 allele in the 3xTg-AD mice. We showed that changing Aβ distribution from the parenchyma to the vasculature drastically reduces the tau pathology. The 3xTg-AD mice expressing the human apoE4 gene were virtually depleted of any somatodendritic tau deposits. These data strongly suggest that the somatodendritic tau accumulation is dependent on the parenchyma Aβ deposits.     

Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options

Tauopathies with parkinsonism represent a spectrum of disease entities unified by the pathologic accumulation of hyperphosphorylated tau protein fragments within the central nervous system. These pathologic characteristics suggest shared pathogenetic pathways and possible molecular targets for disease-modifying therapeutic interventions. Natural history studies, for instance, in progressive supranuclear palsy, frontotemporal dementia with parkinsonism linked to chromosome 17, corticobasal degeneration, and Niemann-Pick disease type C as well as in amyotrophic lateral sclerosis/Parkinson–dementia complex permit clinical characterization of the disease phenotypes and are crucial to the development and validation of biological markers for differential diagnostics and disease monitoring, for example, by use of neuroimaging or proteomic approaches. The wide pathologic and clinical spectrum of the tauopathies with parkinsonism is reviewed in this article, and perspectives on future advances in the understanding of the pathogenesis are given, together with potential therapeutic strategies.     

The complex aetiology of frontotemporal lobar degeneration

Frontotemporal lobar degeneration (FTLD) is now a widely recognised form of dementia. This heterogeneous disease has been of particular interest to geneticists due to its high rate of heritability with up to 40% of patients reporting a family history of the disease in at least one extra family member. There have been several chromosome loci linked to this disorder and three genes have already been identified. Remarkably, it has been recently demonstrated that 2 of these are only 1.7 Mb from one another on chromosome 17q21, these being tau and progranulin. The identification of these genes has contributed greatly to our understanding of the differing neuropathologies associated with FTLD. Furthermore, the discovery that TDP-43 is a component of the neuronal inclusions seen in the most common neuropathological subtype has also helped expand the biochemical pathways that are the focus of much FTLD research. Nevertheless, other genes causing FTLD remain to be identified and their biology elucidated before we have a complete understanding of the complex aetiology of this disease.     

Dynamic association with polysomes during P19 neuronal differentiation and an untranslated-region-dependent translation regulation of the tau mRNA by the tau mRNA-associated proteins IMP1, HuD, and G3BP1

Regulation of mRNA translation is a key step in mediating neuronal polarity during differentiation, insofar as neuronal polarity is partially determined by local translation of specific mRNA molecules as dendrites and axons are emanating. The multiplicity of mRNA-binding proteins in neurons plays an essential role in controlling mRNA translation. These proteins are associated with ribosomes and translation factors, thereby regulating both temporally and spatially the translation process. In a previous study, we have shown an association among the tau mRNA-binding proteins HuD, IMP1, and G3BP1 with translating polysomes in P19 neurons. In the present study, we determined the dynamics of the association among G3BP1, IMP1, and HuD with polysomes through P19 neuronal differentiation as well as the functional effect of these proteins on tau mRNA translation. We show a novel, differentiation-dependent association of these proteins with polysomes. In addition, we show a strong, negative effect on translation of the tau mRNA by IMP1, G3BP1, and HuD proteins in HEK-293 cells. To our knowledge this is the first observation of a direct translational role of G3BP1 for any mRNA and the first report of a translation inhibition by IMP1 and HuD on the tau mRNA in a cell system. The translation inhibition is shown to be mediated by the tau mRNA 3'untranslated regions (UTRs), thus giving a new, translational role for these sequences, which were previously implicated in mRNA stabilization. We also define a novel mechanism for IMP1 binding to tau mRNA, which suggests a conformational binding, which is not sequence dependent.     

The Comorbidity of HIV-Associated Neurocognitive Disorders and Alzheimer’s Disease: A Foreseeable Medical Challenge in Post-HAART Era

Although the introduction of highly active antiretroviral therapy (HAART) has led to a strong reduction of HIV-associated dementia (HAD) incidence, the prevalence of minor HIV-1-associated neurocognitive disorder (HAND) is rising among AIDS patients. HAART medication has shifted neuropathology from a subacute encephalitic condition to a subtle neurodegenerative process involving synaptic and dendritic degeneration, particularly of hippocampal neurons that are spared prior to HAART medication. Considerable neuroinflammation coupled with mononuclear phagocyte activation is present in HAART-medicated brains, particularly in the hippocampus. Accumulating evidence suggests that the resultant elevated secretion of pro-inflammatory cytokines such as interferon-γ, tumor necrosis factor-α, and interleukin-1β can increase amyloid-β peptide (Aβ) generation and reduce Aβ clearance. Recent advancements in Alzheimer’s disease (AD) research identified Aβ biogenesis and clearance venues that are potentially influenced by HIV viral infection, providing new insights into beta-amyloidosis segregation in HIV patients. Our study suggests enhanced beta-amyloidosis in ART-treated HAD and HIV-associated encephalitis brains and suppression of Aβ clearance by viral infection of human primary macrophages. A growing awareness of potential convergent mechanisms leading to neurodegeneration shared by HIV and Aβ points to a significant chance of comorbidity of AD and HAND in senile HIV patients, which calls for a need of basic studies.